Bringing Innovation to Cell and Gene Therapy Manufacturing

The Bio Report
|

Automatic TRANSCRIPT

Farland. Thanks for joining us. Please join me. We're going to talk about or a biotech selling gene manufacturing and the company's efforts to use its platform to bring scouts to the manufacturing of selling gene therapies. Perhaps we can begin with the problem. You're trying to address. How gene and cell therapy is generally manufacturer today and what limitations do existing processes place on access and growth of the market. So i think Selling gene therapies are manufactured in a very similar way as when i scuffles in academic laboratories so that is very manual cell-culture prices which involves quite a lot of people Manley moving cells around the lab genetically modifying them dana cell culture expansion purification and really as you move towards the clinic what The major thing that happens is the those labs academic labs get tun into. Gnp manufacturing sweets where everyone scanned up. Sorry not any of the original problems with being highly money A manual prices in very labor intensive. But then you put on top of that. All of the Extra cleanliness requirements to jam manufacturing. A new end up with really expensive manufacturing prices. That require lots of people. Lots of very high school people actually and also a lot of spice space you need of the amount of Manufacturing facility need to produce a single device is very large. And what that means. Is that if you were to mention. The largest jam. Pay manufacturing site that you could ever imagine struggled to produce more than thousand isis pierre site. That's that's a major issue is selling therapy. Looks to move beyond our initial successes with the coffee therapies full for blood cancers and as we move forward. We're moving towards some really large indications where it's not going to be a case to just produced a fee thousand doses of therapy wigan each produce tens of thousands thousands of doses a moment as it stands. This is physically impossible. It can actually be done. There's no papal The space required is is mind boggling. How much of a bottleneck does manufacturing. The growth of these technologies is commercial products. Yeah this is the major concern. I think a lot of paper looking around investments In this space and they won young startup to have a clear To manufacturing scale and the reason for that is they've seen the struggles of the early entrance into the into the space and it's quite clear the you know the the there. All potential kills under development in very early startups. We may be in a situation. Where unless we get we get a grip of this manufacturing issue. Some of those early startups might stop not to get funded as people start to wonder can have make return on investment in in products or a biotech has developed a manufacturing platform for sale gene therapies. What is the platform consists of. So we've we've gone to some length start with the design for scaled up manufacturing. So how would you manufacture hundred thousand ices back engineered to a single unit on a lab bench and may shoal the pricing unit we designed which intensifies manufacturing automates manufacturing can still be used in an academic lab. So you can still do. You'll preclinical what the amount studies on a on a single already by pricing unit. But the real trick is is the the system is being designed to scale basic level. We've put a load of effort incident. Intensification of the volume. The physical volume needed today. This kind of process and we've come up with some really a novel engineering solutions. Which means that we can stack units horizontally and vertically. They're about the size of a microwave. And because we've brought in the stock ability. What you can do is you can stop envisaging. Scallop of your manufacturing in quite a small area getting to really high three putts. How does this change the manufacturing

Coming up next